These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 12070359)
1. Barriers to Alzheimer disease drug discovery and development in the biotechnology industry. Altstiel LD Alzheimer Dis Assoc Disord; 2002; 16 Suppl 1():S29-32. PubMed ID: 12070359 [TBL] [Abstract][Full Text] [Related]
2. Barriers to drug discovery and development for Alzheimer disease. Fillit HM; O'Connell AW; Brown WM; Altstiel LD; Anand R; Collins K; Ferris SH; Khachaturian ZS; Kinoshita J; Van Eldik L; Dewey CF Alzheimer Dis Assoc Disord; 2002; 16 Suppl 1():S1-8. PubMed ID: 12070355 [TBL] [Abstract][Full Text] [Related]
3. Barriers to Alzheimer disease drug discovery and drug development in the pharmaceutical industry. Anand R Alzheimer Dis Assoc Disord; 2002; 16 Suppl 1():S33-9. PubMed ID: 12070360 [TBL] [Abstract][Full Text] [Related]
4. Barriers to Alzheimer disease drug discovery and development in academia. Van Eldik LJ; Koppal T; Watterson DM Alzheimer Dis Assoc Disord; 2002; 16 Suppl 1():S18-28. PubMed ID: 12070358 [TBL] [Abstract][Full Text] [Related]
5. Industry Perspective on Biomarker Development and Qualification. Gerlach CV; Derzi M; Ramaiah SK; Vaidya VS Clin Pharmacol Ther; 2018 Jan; 103(1):27-31. PubMed ID: 29143971 [TBL] [Abstract][Full Text] [Related]
6. [Historical sketch of modern pharmaceutical science and technology (Part 4). Post World War II 50 years]. Yamakawa K Yakushigaku Zasshi; 1995; 30(2):75-90. PubMed ID: 11613536 [TBL] [Abstract][Full Text] [Related]
7. Medipol: the guardian angel of biologics. Laue C; Ruppanner V Nanomedicine (Lond); 2006 Aug; 1(2):251-4. PubMed ID: 17716114 [TBL] [Abstract][Full Text] [Related]
8. The promise of pharmacogenetics: assessing the prospects for disease and patient stratification. Smart A; Martin P Stud Hist Philos Biol Biomed Sci; 2006 Sep; 37(3):583-601. PubMed ID: 16980196 [TBL] [Abstract][Full Text] [Related]
9. Global Trends in Alzheimer Disease Clinical Development: Increasing the Probability of Success. Sugino H; Watanabe A; Amada N; Yamamoto M; Ohgi Y; Kostic D; Sanchez R Clin Ther; 2015 Aug; 37(8):1632-42. PubMed ID: 26243073 [TBL] [Abstract][Full Text] [Related]
10. A new proposal for randomized start design to investigate disease-modifying therapies for Alzheimer disease. Zhang RY; Leon AC; Chuang-Stein C; Romano SJ Clin Trials; 2011 Feb; 8(1):5-14. PubMed ID: 21335586 [TBL] [Abstract][Full Text] [Related]
11. Target product selection - where can Molecular Pharming make the difference? Paul MJ; Teh AY; Twyman RM; Ma JK Curr Pharm Des; 2013; 19(31):5478-85. PubMed ID: 23394563 [TBL] [Abstract][Full Text] [Related]
12. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
13. Biotechnology in pharmaceuticals: the Japanese challenge. Dibner MD Science; 1985 Sep; 229(4719):1230-5. PubMed ID: 3898361 [TBL] [Abstract][Full Text] [Related]
14. Use of new biotechnology to design rational drugs against newly defined targets. Salfeld JG Best Pract Res Clin Rheumatol; 2004 Feb; 18(1):81-95. PubMed ID: 15123039 [TBL] [Abstract][Full Text] [Related]
15. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease. Shoaib M; Kamal MA; Rizvi SMD Curr Drug Metab; 2017; 18(9):842-852. PubMed ID: 28595531 [TBL] [Abstract][Full Text] [Related]
16. Anticancer Drug Development: The Way Forward. Connors T Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985 [TBL] [Abstract][Full Text] [Related]
17. The optimum time for drug licensing. Kalamas J; Pinkus G Nat Rev Drug Discov; 2003 Sep; 2(9):691-2. PubMed ID: 12953694 [No Abstract] [Full Text] [Related]
18. Rho Chi lecture. Pharmaceutical sciences in the next millennium. Triggle DJ Ann Pharmacother; 1999 Feb; 33(2):241-6. PubMed ID: 10084422 [TBL] [Abstract][Full Text] [Related]